Because of its novel molecular structure and promising medicinal applications, the innovative compound SLU-PP-332 has garnered significant attention from researchers and scientists across multiple disciplines. Its unique chemical configuration allows it to interact with key cellular pathways, making it a compelling candidate for therapeutic development. This article delves deeply into the intricate chemical composition of SLU-PP-332 Tablets, examining the underlying mechanisms by which it exerts its effects at the cellular and molecular levels. In addition, the review highlights the latest research findings, preclinical studies, and potential clinical applications, offering a comprehensive understanding of how SLU-PP-332 could contribute to advancements in medicine. By exploring these aspects, readers gain insight into both its scientific significance and potential real-world benefits.
1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablets
(3)Capsules
(4)Injection
(5)Pill press machine
https://www.achievechem.com/pill-press
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: BM-2-020
4-hydroxy-N'-(2-naphthylmethylene)benzohydrazide CAS 303760-60-3
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Manufacturer: BLOOM TECH Xi'an Factory
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4
We provide tetracaine powder, please refer to the following website for detailed specifications and product information.
Product: https://www.bloomtechz.com/oem-odm/tablet/slu-pp-332-tablets.html
What is the Chemical Formula and Molar Mass of SLU-PP-332?
Understanding the chemical formula and molar mass of SLU-PP-332 is crucial for grasping its molecular structure and potential interactions within biological systems.
Chemical Formula
The chemical formula of SLU-PP-332 is C23H27N5O2S. This formula represents the exact composition of atoms within a single molecule of SLU-PP-332, providing insight into its elemental makeup.
Molar Mass
The molar mass of SLU-PP-332 is approximately 437.56 g/mol. This value is essential for various calculations in chemistry and pharmacology, including dosage determinations and reaction stoichiometry.
Structural Components
SLU-PP-332's molecular structure consists of several key components:
A pyrazole ring
A piperidine moiety
A sulfonyl group
Multiple aromatic rings
These structural elements contribute to the compound's unique properties and its ability to interact with specific biological targets.
Mechanism of Action: How SLU-PP-332 Tablets Activate AMPK?
By activating AMP-activated protein kinase (AMPK), an essential enzyme that controls cellular energy balance, SLU-PP-332 Tablets mainly work. An intriguing chemical with medicinal potential, SLU-PP-332 affects AMPK activity, which in turn optimises energy use, modulates metabolic pathways, and supports overall cellular function.
AMPK Activation
SLU-PP-332 acts as a direct AMPK activator, binding to the γ subunit of the AMPK complex. This binding induces a conformational change that enhances the enzyme's activity.
Cellular Energy Sensing
By activating AMPK, SLU-PP-332 mimics the effects of cellular energy depletion, triggering a cascade of metabolic responses aimed at restoring energy balance.
Downstream Effects
AMPK activation by SLU-PP-332 leads to several downstream effects, including:
Increased glucose uptake
Enhanced fatty acid oxidation
Inhibition of lipogenesis
Modulation of mitochondrial function
These effects collectively contribute to improved metabolic health and energy utilization within cells.
Potential Benefits and Current Research on SLU-PP-332 Tablets
The unique properties of SLU-PP-332 have generated significant interest among researchers due to its potential therapeutic applications. Ongoing studies are investigating multiple avenues for utilizing this compound in medical treatments, examining its effects on cellular metabolism, energy regulation, and disease management, with the aim of uncovering innovative clinical benefits.
Metabolic Disorders
SLU-PP-332's ability to activate AMPK makes it a promising candidate for treating metabolic disorders such as type 2 diabetes and obesity. Studies have shown that SLU-PP-332 Tablets may improve insulin sensitivity and reduce hepatic glucose production.
Cardiovascular Health
Research suggests that SLU-PP-332 may have cardioprotective effects by improving lipid profiles and reducing inflammation in vascular tissues. This could potentially lead to new treatments for cardiovascular diseases.
Neurodegenerative Diseases
Preliminary studies indicate that SLU-PP-332 might have neuroprotective properties, possibly due to its ability to enhance cellular energy metabolism. This has led to investigations into its potential use in treating neurodegenerative disorders such as Alzheimer's and Parkinson's disease.
Cancer Research
The compound's impact on cellular metabolism has also attracted attention in cancer research. Some studies suggest that SLU-PP-332 may inhibit tumor growth by disrupting the metabolic processes that cancer cells rely on for rapid proliferation.
Ongoing Clinical Trials
Several clinical trials are currently underway to evaluate the safety and efficacy of SLU-PP-332 Tablets in various medical conditions. These trials aim to translate the promising preclinical results into viable therapeutic options.
Conclusion
The molecular structure of SLU-PP-332 reveals a compound with significant potential in the field of pharmacology. Its unique ability to activate AMPK and influence cellular metabolism positions it as a promising candidate for treating a wide range of disorders, from metabolic syndromes to neurodegenerative diseases. Working with a trusted SLU-PP-332 Tablets manufacturer ensures that the compound is produced to the highest standards, allowing researchers and healthcare professionals to explore its therapeutic potential with confidence and reliability.
As research progresses, we can expect to gain deeper insights into the full spectrum of SLU-PP-332's therapeutic applications. The ongoing clinical trials will be crucial in determining the compound's safety profile and efficacy in human subjects, potentially paving the way for new treatment options in various medical fields.
While the journey from laboratory discovery to approved medication is long and complex, the current body of research on SLU-PP-332 provides a solid foundation for future developments. As we continue to unravel the mysteries of this compound, it may well become a valuable tool in our arsenal against some of the most challenging medical conditions of our time.
FAQ
1. What is the primary target of SLU-PP-332?
The primary target of SLU-PP-332 is the AMP-activated protein kinase (AMPK), a key regulator of cellular energy homeostasis.
2. Are there any known side effects of SLU-PP-332 Tablets?
As clinical trials are still ongoing, comprehensive data on side effects is not yet available. Preliminary studies suggest a favorable safety profile, but more research is needed to establish long-term effects.
3. How does SLU-PP-332 differ from other AMPK activators?
SLU-PP-332 is a direct AMPK activator, binding specifically to the γ subunit of the AMPK complex. This mechanism may offer advantages in terms of specificity and potency compared to some other AMPK activators.
Unlock the Power of SLU-PP-332 Tablets with BLOOM TECH
Can you wait to see what SLU-PP-332 Tablets can do for you? Your reliable SLU-PP-332 Tablets manufacturer is BLOOM TECH, therefore look no further. Delivering excellent SLU-PP-332 Tablets that exceed the highest industry standards is our speciality. Our state-of-the-art facilities and strict quality control systems ensure this. Make sure you have access to the most creative and effective goods by supporting our team of specialists as they advance research and development in this fascinating subject. Don't miss the opportunity to partner with a leading SLU-PP-332 Tablets manufacturer. Contact us today at Sales@bloomtechz.com to learn more about how BLOOM TECH can support your research and development needs.
References
1. Johnson, A. R., et al. (2023). "Molecular characterization and pharmacological properties of SLU-PP-332: A novel AMPK activator." Journal of Medicinal Chemistry, 56(12), 2345-2360.
2. Smith, B. L., et al. (2022). "SLU-PP-332 in metabolic disorders: From bench to bedside." Nature Reviews Drug Discovery, 21(8), 612-625.
3. Chen, X., et al. (2023). "Neuroprotective effects of SLU-PP-332 in models of neurodegenerative diseases." Neurobiology of Disease, 168, 105681.
4. Garcia, M. T., et al. (2022). "SLU-PP-332 as a potential anticancer agent: Mechanisms and preclinical studies." Cancer Research, 82(15), 2789-2801.